Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORETHIN 1/50M-21 vs ESTARYLLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Treatment of endometriosis,Treatment of abnormal uterine bleeding,Contraception,Amenorrhea,Palliative treatment of advanced breast cancer (off-label)
FDA-approved: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.,Off-label: Acne vulgaris (for norgestimate-containing pills), management of menstrual disorders (e.g., dysmenorrhea, abnormal uterine bleeding), hormone therapy for transgender women (non-standardized).,Note: Off-label uses are not FDA-approved for this specific formulation.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
Terminal elimination half-life: 5-14 hours (mean ~8h). Clinical context: Steady-state achieved after 4-5 days; dosing interval 24 hours maintains therapeutic levels.
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Hepatic metabolism primarily via reduction and conjugation; minor CYP3A4 involvement. Metabolites are excreted in urine and feces.
Ethinyl estradiol is primarily metabolized by CYP3A4, with conjugation to glucuronides and sulfates. Norgestimate is rapidly metabolized to its active metabolite, norelgestromin, and further to levonorgestrel; involvement of CYP2C19 and CYP3A4 in norgestimate metabolism is noted.
Renal: 50-60% as metabolites; Fecal: 30-40% (via biliary); Less than 5% unchanged in urine.
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
97-98% bound; primarily to albumin (70%) and SHBG (30%).
Ethinyl estradiol: 97-98% bound to albumin, with minor binding to sex hormone-binding globulin
3.6-4.7 L/kg; indicates extensive tissue distribution, including breast tissue and adipose.
Ethinyl estradiol: approximately 2.8 L/kg; indicates extensive tissue distribution
Oral: 64-76% (first-pass metabolism reduces bioavailability).
Oral: approximately 55% due to first-pass metabolism; consistent in healthy females
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment or end-stage renal disease due to lack of data.
Contraindicated in hepatic impairment, including active liver disease, jaundice, or Child-Pugh class B or C. No studies for mild impairment; use not recommended.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; dose adjustment not specifically defined, but alternative contraception recommended.
Not indicated for use before menarche. Post-menarche, use same dosing as adults (one tablet daily) with monitoring for thromboembolic risks.
Approved for use in postmenarchal adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). No weight-based dosing required.
Not indicated for postmenopausal women. In older reproductive-age women, use same adult dosing; monitor for cardiovascular and thromboembolic risks due to higher estrogen dose.
Not indicated in postmenopausal women. No specific geriatric dosing; contraindicated in women over 60 years due to increased thromboembolic risk.
Cigarette smoking increases the risk of serious cardiovascular side effects from combined oral contraceptives. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is marked in women over 35 years who smoke. Combined oral contraceptives should not be used by women over 35 years who smoke.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptives. This risk increases with age (especially in women over 35 years of age) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders, especially in smokers over 35. Hepatotoxicity risk. May cause fluid retention. Monitor for depression, elevated blood pressure, and glucose intolerance. Discontinue if jaundice or visual disturbances occur.
Thrombotic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., MI, stroke). Discontinue if thrombotic event occurs.,Cardiovascular disease: Avoid in women with uncontrolled hypertension, diabetes with vascular involvement, or history of thromboembolic disease.,Cigarette smoking: Strongly advise cessation, especially in women over 35.,Liver disease: Discontinue if jaundice or cholestasis develops; contraindicated in acute viral hepatitis or severe cirrhosis.,Hormone-dependent malignancies: Increased risk of breast cancer (current use) and cervical cancer; avoid if known or suspected breast cancer.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate and lipid metabolism: Monitor glucose and lipids in predisposed patients; may impair glucose tolerance and increase triglycerides.,Headache: Evaluate if new-onset or worsening migraine, especially with focal neurological symptoms.,Uterine bleeding: Rule out pregnancy if amenorrhea occurs; irregular bleeding may require evaluation.,Depression: Monitor for mood changes; discontinue if severe depression recurs.,Angioedema: Risk in women with hereditary angioedema.
Known or suspected pregnancy, history of or current thrombophlebitis or thromboembolic disorders, cerebrovascular disease, coronary artery disease, hepatic impairment or liver tumors, undiagnosed abnormal uterine bleeding, known or suspected breast carcinoma (unless for palliation), hypersensitivity to norethindrone.
Known or suspected pregnancy,Current or past venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism),Current or past arterial thrombosis (e.g., myocardial infarction, stroke) or prodromal conditions (e.g., angina, transient ischemic attack),Known thrombophilic disorders (e.g., Factor V Leiden, prothrombin mutation, antithrombin deficiency),History of cerebrovascular or coronary artery disease,Uncontrolled hypertension (sustained >160/100 mm Hg),Diabetes mellitus with nephropathy, retinopathy, neuropathy, or other vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura) in women over 35,Current or past breast cancer, or other estrogen- or progestin-sensitive cancer,Active liver disease (e.g., acute viral hepatitis, severe cirrhosis) or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component of Estarylla,Use of highly active antiretroviral therapy (HAART) containing ritonavir or direct-acting antivirals for hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir) due to potential for hepatotoxicity
No significant food interactions. However, maintaining a consistent diet is recommended to avoid gastrointestinal upset. Grapefruit juice may inhibit CYP3A4 and increase estrogen levels, but clinical significance is low.
There are no known significant food interactions. Grapefruit juice may increase estrogen levels but clinical significance is unclear; consider moderate intake.
Contraindicated in pregnancy. First trimester: Association with cardiovascular defects and limb reduction defects (case-control studies show odds ratio 1.3-2.8 for oral contraceptive use). Second and third trimesters: No increased risk of major malformations if inadvertently exposed; however, hormones can affect fetal endocrine development. Use is not recommended during any trimester.
Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations from inadvertent exposure, but increased risk of cardiovascular and limb defects in some studies. Second and third trimesters: Associated with fetal harm, including cardiovascular effects (e.g., congenital heart defects) and possible estrogenic effects, though data are limited. Postnatal effects: Potential long-term developmental effects unknown. Overall risk is low but not zero; avoid use in pregnancy.
Excreted in breast milk in small amounts (estrogen and progestin). M/P ratio not established for this fixed-dose combination. May reduce milk production and composition, especially in early postpartum. American Academy of Pediatrics considers use compatible with breastfeeding, but alternative contraception recommended. Monitor infant for jaundice and weight gain.
Estarylla is excreted in breast milk in small amounts (ethinyl estradiol: M/P ratio ~0.2; levonorgestrel: M/P ratio ~0.3-0.4). Combined hormonal contraceptives may reduce milk production and affect milk composition, especially in early postpartum. Use is generally not recommended until breastfeeding is well-established (at least 6 weeks postpartum). For later use, progestin-only methods are preferred. Monitor infant for jaundice and growth.
Contraindicated in pregnancy; no dose adjustment applicable. If used inadvertently, discontinue immediately. No pharmacokinetic studies in pregnancy due to contraindication. Theoretical decreased contraceptive efficacy during pregnancy is irrelevant.
Estarylla is contraindicated in pregnancy. No dosing adjustments are recommended because it should not be used. Pregnancy alters pharmacokinetics of oral contraceptives (e.g., increased volume of distribution, altered hepatic metabolism), but no dose changes are indicated due to contraindication. If inadvertently taken, discontinue immediately.
Monitor for thromboembolic events, especially in smokers over 35. Advise use of barrier contraception to reduce STI risk. Assess blood pressure at baseline and follow-up due to potential estrogenic effects. May reduce menstrual flow and dysmenorrhea.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It is indicated for prevention of pregnancy. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed dose management: take as soon as remembered, use backup contraception if more than 24 hours late. May reduce menstrual cramps and acne. Not recommended in patients with history of estrogen-dependent neoplasia, liver disease, or uncontrolled hypertension.
Take one tablet daily at the same time, even if you do not have sex.,If you miss a pill, follow the package instructions or consult your healthcare provider.,Smoking while taking this pill increases risk of blood clots, especially if over age 35.,This pill does not protect against HIV or other sexually transmitted infections.,Contact your doctor if you experience severe headaches, vision changes, or leg pain/swelling.
Take one pill daily at the same time each day.,If you miss a pill, take it as soon as remembered; use backup contraception if more than 24 hours late.,Do not smoke while taking this medication, especially if over 35.,Report any signs of blood clots: leg pain, chest pain, shortness of breath, or sudden vision changes.,This medication does not protect against HIV or other STDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORETHIN 1/50M-21 vs ESTARYLLA, answered by our medical review team.
NORETHIN 1/50M-21 is a Combined Oral Contraceptive that works by Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. ESTARYLLA is a Combined Oral Contraceptive that works by Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORETHIN 1/50M-21 and ESTARYLLA depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORETHIN 1/50M-21 is: One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ESTARYLLA is: One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORETHIN 1/50M-21 and ESTARYLLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORETHIN 1/50M-21 is classified as Category C. Contraindicated in pregnancy. First trimester: Association with cardiovascular defects and limb reduction defects (case-control studies show odds ratio 1.3-2.8 for oral contracepti. ESTARYLLA is classified as Category C. Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.